APA (7th ed.) Citation

S, L., E, A., L, R., Z, C., S, C., P, F., . . . L, B. (2019). Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE. The oncologist, 24(6), e232. https://doi.org/10.1634/theoncologist.2017-0676

Chicago Style (17th ed.) Citation

S, Leo, et al. "Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE." The Oncologist 24, no. 6 (2019): e232. https://doi.org/10.1634/theoncologist.2017-0676.

MLA (9th ed.) Citation

S, Leo, et al. "Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE." The Oncologist, vol. 24, no. 6, 2019, p. e232, https://doi.org/10.1634/theoncologist.2017-0676.